GSK3036656

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Tuberculosis

Phase 1

First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects

CompletedNCT03075410

GlaxoSmithKlineTuberculosis

Start: 2017-04-02End: 2017-08-04Updated: 2019-04-19

A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age

CompletedNCT06354257

GlaxoSmithKlineTuberculosis

Start: 2024-04-05End: 2024-07-01Updated: 2025-08-26

Phase 2

An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

CompletedNCT03557281

GlaxoSmithKlineTuberculosis

Start: 2019-03-22End: 2021-12-14Updated: 2023-10-26

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

CompletedNCT05382312

GlaxoSmithKlineTuberculosis

Start: 2022-07-26End: 2025-05-27Updated: 2025-10-07

Related Papers

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.

2024-02-1625 citations

First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment.

2019-07-2549 citations